🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Unlearn.AI welcomes AstraZeneca CMO Ann Taylor, MD, to our Board of Directors. Read the press release to learn more about how Dr. Taylor, a leading clinical development expert, will help us expand the impact of #AI-based technologies in #clinicaltrials. bwnews.pr/30yl6eo

Why are ultraconserved enhancer sequences ultraconserved? Our latest attempt to solve the mystery, led by Valentina Snetkova Here is the TL;DR thread (1/n) nature.com/articles/s4158…

A fun project from the spring - a planter for Diane's home office. About 28"x12"x32", designed and built as I went. The sides are cedar tongue-and-grooves slats, framed with oak. Paduak rails support the pot on the bottom and connect to the legs, which are jatoba.

I have a lot of finished projects that I've not posted. This a project from last summer, a painted carving in basswood about 18 inches square. Painted by me and Vivian. Took a lot of work to get a black/gold effect I liked, and learned a lot about carving, gesso, and painting.

.Unlearn.AI is thrilled to announce a multi-year collaboration with Merck KGaA, Darmstadt, Germany to accelerate late-stage clinical trials with novel trial designs that include #DigitalTwins, with an initial focus on immunology. #AI bwnews.pr/3rRPQpg

Unlearn is hiring for a Head of Biostatistics Research and will be reviewing applications and scheduling interviews during JSM 2022. All registered applicants can apply through the JSM Career Portal, here: bit.ly/3RFitB0 @Amstatnews

Once you can do things, what you do is one of the most important decisions you will make. This has to be in the top 3 of advice I've ever gotten, and I think about it more and more often. What you work on is worth deep thought, even daily.

Not all data-driven covariate adjustment methods are created equal! Our prognostic covariate adjustment method, PROCOVA™, adjusts for AI-derived forecasts of participants’ clinical outcomes to increase the efficiency of #clinicaltrials.

🎉 Thrilled to announce that we’ve secured a $50M Series C funding round led by Altimeter, joined by returning investors Radical Ventures, Wittington Ventures, Mubadala Capital, EPIC Ventures, and Necessary Ventures. This investment in our talented team, our data and engineering capabilities,